410 related articles for article (PubMed ID: 33983833)
1. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.
Hahn VS; Zhang KW; Sun L; Narayan V; Lenihan DJ; Ky B
Circ Res; 2021 May; 128(10):1576-1593. PubMed ID: 33983833
[TBL] [Abstract][Full Text] [Related]
2. Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):250-257. PubMed ID: 31988685
[TBL] [Abstract][Full Text] [Related]
3. Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Brown SA; Ray JC; Herrmann J
J Cardiovasc Transl Res; 2020 Jun; 13(3):402-416. PubMed ID: 32253744
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
[TBL] [Abstract][Full Text] [Related]
5. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
6. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity.
Lang NN; Touyz RM
Clin Sci (Lond); 2021 Dec; 135(23):2661-2663. PubMed ID: 34881389
[TBL] [Abstract][Full Text] [Related]
8. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of cancer chemotherapy in clinical practice.
Jain D; Aronow W
Hosp Pract (1995); 2019 Feb; 47(1):6-15. PubMed ID: 30270693
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
[TBL] [Abstract][Full Text] [Related]
11. Cardio-oncology: management of cardiovascular toxicity.
Markman TM; Markman M
F1000Res; 2019; 8():. PubMed ID: 30755794
[TBL] [Abstract][Full Text] [Related]
12. Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy.
Kenigsberg B; Jain V; Barac A
Heart Fail Clin; 2017 Apr; 13(2):297-309. PubMed ID: 28279416
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
Brower V
J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
[No Abstract] [Full Text] [Related]
15. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
16. Assessment and Management of Cardiotoxicity in Hematologic Malignancies.
Bojan A; Torok-Vistai T; Parvu A
Dis Markers; 2021; 2021():6616265. PubMed ID: 33613788
[TBL] [Abstract][Full Text] [Related]
17. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection.
Deidda M; Mercurio V; Cuomo A; Noto A; Mercuro G; Cadeddu Dessalvi C
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590338
[TBL] [Abstract][Full Text] [Related]
20. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Guha A; Armanious M; Fradley MG
Trends Cardiovasc Med; 2019 Jan; 29(1):29-39. PubMed ID: 29910109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
